Arvind Utchanah
Director of Finance/CFO presso KNIGHT THERAPEUTICS INC.
Patrimonio netto: 153 413 $ in data 31/03/2024
Profilo
Arvind Utchanah is currently the Chief Financial Officer at Knight Therapeutics, Inc. He previously worked as the Director-Finance, Accounting & Financial Planning at Paladin Labs, Inc. from 2012 to 2016.
Mr. Utchanah has an undergraduate degree from McGill University and a graduate degree from Concordia University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 12/04/2024 | 39 136 ( 0.04% ) | 153 413 $ | 31/03/2024 |
Posizioni attive di Arvind Utchanah
| Società | Posizione | Inizio |
|---|---|---|
| KNIGHT THERAPEUTICS INC. | Director of Finance/CFO | 30/03/2020 |
Precedenti posizioni note di Arvind Utchanah
| Società | Posizione | Fine |
|---|---|---|
| PALADIN LABS INC. | Director of Finance/CFO | 01/06/2016 |
Formazione di Arvind Utchanah
| McGill University | Undergraduate Degree |
| Concordia University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| KNIGHT THERAPEUTICS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Paladin Labs, Inc.
 Paladin Labs, Inc. Pharmaceuticals: MajorHealth Technology Paladin Labs Inc. operates as pharmaceutical company. It engages in developing, acquiring, in-licensing, marketing, and distributing innovative pharmaceutical products in Canada and internationally. The firm's products include Abstral, GlucaGen, Metadol, Plan B, Pennsaid, Seasonale, Testim, Twinject, Dexedrin, Tridural, and Trelstar. The company was founded by Jonathan Ross Goodman and Mark Beaudet on February 25, 1983 and is headquartered in Montreal, Canada. | Health Technology |
- Borsa valori
- Insiders
- Arvind Utchanah
